Evidence analysisOctober 16, 2026Health & Science
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It targets two immune system messenger molecules, interleukin 12 (IL-12) and interleukin 23 (IL-23), both implicated in inflammatory processes underlying these conditions.
Clinical trials in adults have shown that Stelara can significantly reduce disease symptoms compared to placebo in all indicated diseases. In plaque psoriasis, approximately 69% of adults achieved a 75% or greater symptom improvement by 12 weeks compared to about 3% on placebo. Similar efficacy was observed in psoriatic arthritis and Crohn’s disease studies with symptom improvement rates roughly doubling versus placebo. Pediatric studies involving children as young as 2 years for Crohn’s disease and 6 years for psoriasis demonstrated comparable effectiveness, although some trials lacked placebo or active comparators.
The dosing regimen varies by condition, initially involving an infusion for Crohn’s and ulcerative colitis, followed by subcutaneous injections every 8 to 12 weeks. Patients are typically supervised by specialists experienced in these diseases, and some may self-administer after training.
What the source claims
- Stelara’s active substance, ustekinumab, blocks IL-12 and IL-23, reducing immune-mediated inflammation in target diseases.
- The drug is indicated for use when patients have failed, cannot tolerate, or are unsuitable for prior systemic therapies including conventional immunosuppressants or phototherapy.
- Clinical trials provide evidence of superior efficacy of Stelara versus placebo in adults and children, with maintained benefit over up to 5 years in psoriasis.
- In psoriasis, Stelara was shown to be more effective than etanercept, another biologic treatment.
- In Crohn’s disease and ulcerative colitis, Stelara treatment starts with intravenous infusion followed by maintenance subcutaneous injections, with positive response rates reported for adults and children.
What may be missing from the usual framing
The source is a regulatory public assessment report, which emphasizes data from pivotal clinical trials submitted for marketing approval, focusing on efficacy and initial safety within controlled study settings. The framing may underrepresent:
- Long-term real-world safety data beyond five years or in diverse populations including those with complex comorbidities.
- Comparative effectiveness and safety against a broader range of alternative therapies beyond etanercept in psoriasis.
- Detailed reporting of adverse effects and risk-benefit considerations in pediatric populations, as some pediatric studies were open-label or lacked control groups.
- Economic considerations such as cost-effectiveness, accessibility barriers, or patient adherence challenges with injection therapy.
Competing evidence or uncertainty
The EMA report does not provide extensive information on post-marketing surveillance or independent effectiveness studies. Key uncertainties that remain and require further investigation include:
- Long-term risks of immunosuppression with ustekinumab, such as infections or malignancies, outside clinical trial conditions.
- Variability in patient response, including mechanisms of resistance or loss of therapeutic effect over time.
- Precise positioning of Stelara in treatment algorithms compared to other biologics or new therapies entering the market.
- Whether pediatric dosing and safety profiles adequately predict rare but serious adverse outcomes given smaller study sizes.
Why it matters
Chronic inflammatory diseases treated by Stelara often cause significant morbidity and impact quality of life. Access to effective therapies that provide durable symptom control or remission can reduce disease burden and healthcare costs. Understanding the full evidence for Stelara’s efficacy, safety, and optimal use ensures informed treatment decisions by clinicians, patients, and policymakers.
Given the increasing availability of biologic treatments and expanding indications, transparent independent evidence review is critical to weigh benefits, risks, and resource allocation. Highlighting knowns and unknowns also supports ongoing monitoring, patient education, and future research priorities.
What to verify next
Readers interested in a comprehensive and balanced perspective on Stelara should verify the following:
- Updated post-marketing safety data and real-world effectiveness studies published since the latest EMA report.
- Comparative studies involving other biologics and emerging treatments to understand positioning and relative advantages.
- Patient-reported outcomes and quality-of-life measures beyond clinical symptom scores.
- Practical considerations in treatment administration, including patient adherence, injection site reactions, and monitoring requirements.
- Regulatory updates, including new indications, contraindications, or safety warnings issued by authorities.
For detailed information, consulting the original EMA human medicines European public assessment report and the product’s official prescribing information is advisable.
Source & verification
Primary source: What's new · October 16, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…